Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|November 11, 2015
TrakCel Ltd. Adds Cognate BioSevices to Connected Services Program
Author(s)Pharmaceutical Technology Editors
Advertisement
TrakCel Ltd., a cell therapy process management and supply chain integration technology, recently introduced Cognate BioServices as the newest member of its Connected Service program,
Cognate Bioservices is a fully integrated contract bioservices organization providing development and cGMP-manufacturing services to institutions engaged in the development of cell-based products.
The Connected Services partner ecosystem accelerates cell therapy success by enhancing TrakCel's cell therapy supply chain management platform, according to TrakCel. This improvement to the platform supports therapy success by providing links to participant firms specializing in logistics, cell therapy manufacturing, patient treatment, storage, and compliance.
TrakCel’s technology provides additional transparency into the entire cell therapy process, while providing real-time audit logs and chain-of-custody records of critical components.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement